IBA SA : IBA Signs Contract to Install Proteus®ONE Compact Proton Therapy Center in Abu Dhabi, UAE
27 Septembre 2016 - 7:00AM
IBA Signs Contract
to Install Proteus®ONE
Compact Proton Therapy Center in Abu Dhabi,
UAE
Contract based on previously announced letter of
intent to install Proteus®ONE
center
Louvain-la-Neuve,
Belgium, September 27, 2016 - IBA (Ion Beam Applications S.A.),
the world's leading provider of proton therapy solutions for the
treatment of cancer, announces today that it has signed a contract
with Proton Partners International (PPI) to install a Proteus®ONE*
compact proton therapy solution in a private clinic in Abu Dhabi,
UAE.
This will be the first ever
compact proton therapy solution to be sold and installed in the
Middle East region.
The contract, which was previously
announced upon the signing of a letter of intent in an IBA press
release dated June 28th 2016, covers
delivery of the Proteus®ONE equipment,
including Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT)
capabilities, making it the compact solution best suited for
Adaptive Treatment. The contract also includes a maintenance
agreement. The typical end-user price for a Proteus®ONE
solution with a maintenance contract is between EUR 35 and 40
million.
This project, the fourth center to
be built for PPI, is part of a framework agreement that IBA and
Philips signed in September 2014 to advance the diagnosis and
treatment of cancer.
Olivier Legrain,
Chief Executive Officer of IBA, commented: "Proton Partners
International's partnership with IBA, born from IBA's longstanding
partnership with Philips, not only strengthens our world leading
position in proton therapy, but also highlights the preference of
IBA as the most experienced and most reliable proton therapy
provider in the market with the fastest delivery times. We are
excited about our first project in the Middle East, a region that
holds tremendous potential for proton therapy."
Mike Moran, Chief
Executive Officer of Proton Partners International Limited,
added: "We have been extremely satisfied with our collaboration
with IBA and thus it was a natural choice to select IBA for our new
project in the Middle East. We are excited about the opportunity to
deliver the first proton therapy centre in Abu Dhabi, UAE and we
look forward to working with a range of stakeholders to help
support the research effort in the wider use of proton beam therapy
for the benefit of the patients from all over Middle East
region."
- Ends -
About Proteus®ONE
Proteus®ONE is the
compact intensity modulated proton therapy (IMPT) solution from
IBA. It benefits from the latest technologies developed with
renowned clinical institutions. Proteus®ONE is
smaller, more affordable, easier to install and to operate. It is
ultimately easier to finance, making this advanced radiation
therapy modality available to more institutions and patients
worldwide. Proteus®ONE makes
proton herapy easy.
* Proteus®ONE is the
brand name of a Proteus®235
configuration
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA's
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room systems. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry.
Headquartered in Belgium and
employing about 1,400 people worldwide, IBA has installed systems
across the world. IBA is listed on the pan-European stock exchange
EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more
information can be found at: www.iba-worldwide.com
About Proton
Partners International Limited
Proton Partners International is a private limited company,
registered in Wales. The company was formed following discussions
between Professor Karol Sikora, former head of the World Health
Organisation's cancer programme, Professor Sir Chris Evans, the
leading life sciences entrepreneur, and Neil Woodford, founding
partner of Woodford Investment Management. Institutional and
private investors have committed to almost £100m equity finance in
the company.
Professor Gordon McVie, Senior
Consultant at the European Institute of Oncology, has been
appointed chairman, Professor Karol Sikora is Chief Medical Advisor
and one of the Founders, Mike Moran has been appointed as the Chief
Executive Officer. www.proton-int.com
For further information please
contact:
IBA
Investor Relations
Jean-Marc Bothy
Chief Strategy Officer
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Media Relations
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com |
For media and investor
enquiries:
Consilium Strategic Communications
Jonathan Birt, Matthew Neal, Ivar Milligan, Melissa
Gardiner
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+ 1 917 322 2571
IBA@RxIR.com
|
PPI-final-signature_EN-22 09
16-UAE
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024